# Bortezomib and High-dose Melphalan at Myeloma Relapse

> **NCT00508209** · PHASE2 · UNKNOWN · sponsor: **Nordic Myeloma Study Group** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00508209
- **Lead sponsor:** Nordic Myeloma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-07
- **Primary completion:** 2009-06
- **Final completion:** 2010-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2010-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508209, "Bortezomib and High-dose Melphalan at Myeloma Relapse". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00508209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*